JP2016506761A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506761A5 JP2016506761A5 JP2015558224A JP2015558224A JP2016506761A5 JP 2016506761 A5 JP2016506761 A5 JP 2016506761A5 JP 2015558224 A JP2015558224 A JP 2015558224A JP 2015558224 A JP2015558224 A JP 2015558224A JP 2016506761 A5 JP2016506761 A5 JP 2016506761A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- polypeptide
- mouse
- mhc
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766762P | 2013-02-20 | 2013-02-20 | |
| US61/766,762 | 2013-02-20 | ||
| US201361890915P | 2013-10-15 | 2013-10-15 | |
| US61/890,915 | 2013-10-15 | ||
| PCT/US2014/017395 WO2014130671A1 (en) | 2013-02-20 | 2014-02-20 | Mice expressing humanized t-cell co-receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018100545A Division JP6752842B2 (ja) | 2013-02-20 | 2018-05-25 | ヒト化ｔ細胞補助受容体を発現するマウス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506761A JP2016506761A (ja) | 2016-03-07 |
| JP2016506761A5 true JP2016506761A5 (enExample) | 2017-03-23 |
| JP6444895B2 JP6444895B2 (ja) | 2018-12-26 |
Family
ID=50236327
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558224A Active JP6444895B2 (ja) | 2013-02-20 | 2014-02-20 | ヒト化ｔ細胞補助受容体を発現するマウス |
| JP2018100545A Active JP6752842B2 (ja) | 2013-02-20 | 2018-05-25 | ヒト化ｔ細胞補助受容体を発現するマウス |
| JP2020138641A Active JP7261772B2 (ja) | 2013-02-20 | 2020-08-19 | ヒト化ｔ細胞補助受容体を発現するマウス |
| JP2022094953A Pending JP2022121465A (ja) | 2013-02-20 | 2022-06-13 | ヒト化ｔ細胞補助受容体を発現するマウス |
| JP2023191033A Active JP7883476B2 (ja) | 2013-02-20 | 2023-11-08 | ヒト化ｔ細胞補助受容体を発現するマウス |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018100545A Active JP6752842B2 (ja) | 2013-02-20 | 2018-05-25 | ヒト化ｔ細胞補助受容体を発現するマウス |
| JP2020138641A Active JP7261772B2 (ja) | 2013-02-20 | 2020-08-19 | ヒト化ｔ細胞補助受容体を発現するマウス |
| JP2022094953A Pending JP2022121465A (ja) | 2013-02-20 | 2022-06-13 | ヒト化ｔ細胞補助受容体を発現するマウス |
| JP2023191033A Active JP7883476B2 (ja) | 2013-02-20 | 2023-11-08 | ヒト化ｔ細胞補助受容体を発現するマウス |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9848587B2 (enExample) |
| EP (3) | EP2958938B1 (enExample) |
| JP (5) | JP6444895B2 (enExample) |
| KR (5) | KR102579405B1 (enExample) |
| CN (2) | CN105164153B (enExample) |
| AU (4) | AU2014218897C1 (enExample) |
| CA (1) | CA2900832A1 (enExample) |
| CY (1) | CY1121979T1 (enExample) |
| DK (1) | DK2958938T3 (enExample) |
| ES (2) | ES2736052T3 (enExample) |
| HR (1) | HRP20191280T1 (enExample) |
| HU (1) | HUE045478T2 (enExample) |
| LT (1) | LT2958938T (enExample) |
| PL (1) | PL2958938T3 (enExample) |
| PT (1) | PT2958938T (enExample) |
| RS (1) | RS58962B1 (enExample) |
| SI (1) | SI2958938T1 (enExample) |
| SM (1) | SMT201900429T1 (enExample) |
| WO (1) | WO2014130671A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102295746B1 (ko) | 2011-10-28 | 2021-09-01 | 리제너론 파아마슈티컬스, 인크. | 유전자 변형된 주요 조직적합성 복합체 마우스 |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| RS63220B1 (sr) | 2011-10-28 | 2022-06-30 | Regeneron Pharma | Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc) |
| US9848587B2 (en) * | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| HRP20231121T1 (hr) | 2013-09-23 | 2023-12-22 | Regeneron Pharmaceuticals, Inc. | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale |
| MY183188A (en) | 2013-11-19 | 2021-02-18 | Regeneron Pharma | Non-human animals having a humanized b-cell activating factor gene |
| RS60398B1 (sr) | 2014-04-08 | 2020-07-31 | Regeneron Pharma | Ne-humane životinje sa humanizovanim fc-gama receptorima |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| WO2015196051A1 (en) | 2014-06-19 | 2015-12-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| US20160081314A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| BR112017010793A2 (pt) * | 2014-11-24 | 2017-12-26 | Regeneron Pharma | animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo. |
| BR112017010490A2 (pt) | 2014-12-05 | 2018-04-03 | Regeneron Pharma | roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. |
| ES2841353T3 (es) * | 2014-12-09 | 2021-07-08 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado |
| MX2017012829A (es) | 2015-04-06 | 2018-02-23 | Regeneron Pharma | Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. |
| MA44907A (fr) * | 2015-09-11 | 2018-07-18 | Agenus Inc | Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation |
| CN108366548B (zh) | 2015-11-20 | 2021-10-08 | 瑞泽恩制药公司 | 具有人源化淋巴细胞活化基因3的非人动物 |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| WO2017150763A1 (ko) * | 2016-02-29 | 2017-09-08 | (주)메디톡스 | 인간 cd3 발현 동물모델 및 이의 용도 |
| CN109640644B (zh) | 2016-06-03 | 2021-10-26 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| IL277355B2 (en) | 2018-03-26 | 2025-01-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| AU2019256536C1 (en) | 2018-04-19 | 2026-01-15 | Baylor College Of Medicine | Reprogramming CD4 T cells into cytotoxic CD8 cells by forced expression of CD8αβ and Class 1 restricted T cell receptors |
| CA3098040A1 (en) | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of ditra disease and uses thereof |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
| CN116981357A (zh) | 2021-03-31 | 2023-10-31 | 瑞泽恩制药公司 | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 |
| CA3265746A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF A HUMAN CELLULAR IMMUNE SYSTEM |
| TW202520975A (zh) | 2023-08-09 | 2025-06-01 | 英商劍橋企業有限公司 | 基因改造之囓齒動物及囓齒動物細胞以及其等用途 |
| GB2640828A (en) | 2024-04-22 | 2025-11-12 | T Therapeutics Ltd | Methods and products for the generation and identification of T cells and TCRs |
| GB2642411A (en) | 2024-04-22 | 2026-01-14 | T Therapeutics Ltd | T Cell Receptor identification and provision |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958678A (en) * | 1986-08-21 | 1999-09-28 | The Trustees Of Columbia University In The City Of New York | DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| DE69034263D1 (de) | 1989-07-25 | 2009-04-02 | Cell Genesys Inc | Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| WO1993005817A1 (en) | 1991-09-19 | 1993-04-01 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | TRANSGENIC ANIMALS HAVING TARGET LYMPHOCYTA TRANSDUCTION GENES. |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| EP0910409A4 (en) | 1996-03-05 | 2003-03-19 | Scripps Research Inst | RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| WO2001027291A1 (en) | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JPWO2002047474A1 (ja) | 2000-12-13 | 2004-04-15 | 住友製薬株式会社 | Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用 |
| DK1409646T3 (da) | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
| ATE438710T1 (de) * | 2001-05-15 | 2009-08-15 | Ortho Mcneil Janssen Pharm | Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen |
| FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| EP1616016B1 (en) | 2003-03-19 | 2012-11-14 | Isogenis, Inc. | Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| US7745690B2 (en) | 2004-03-09 | 2010-06-29 | Nagoya Industrial Science Research Institute | Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis |
| CA2574802A1 (en) | 2004-07-20 | 2006-02-02 | Isogenis, Inc. | Specific inhibition of autoimmunity and diseases associated with autoantigens |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| EP2262898B1 (en) | 2008-03-07 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Es cell-derived mice from diploid host embryo injection |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| PL2346994T3 (pl) | 2008-09-30 | 2022-04-19 | Ablexis, Llc | Myszy knock-in do wytwarzania chimerycznych przeciwciał |
| WO2010099463A2 (en) * | 2009-02-27 | 2010-09-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Joint bioscaffolds |
| DK3241435T3 (da) * | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| GB2472108B (en) | 2009-08-27 | 2011-07-13 | Budha Singh Dhinjan | Wall bead |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| WO2011100761A2 (en) * | 2010-02-15 | 2011-08-18 | Indiana University Research And Technology Corporation | Cd4 t-cells involved in mammalian host response to epithelial cell infection and uses thereof |
| NZ602220A (en) | 2010-03-11 | 2014-10-31 | Rinat Neuroscience Corp | Antibodies with ph dependent antigen binding |
| WO2012039779A1 (en) | 2010-09-24 | 2012-03-29 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| KR102295746B1 (ko) | 2011-10-28 | 2021-09-01 | 리제너론 파아마슈티컬스, 인크. | 유전자 변형된 주요 조직적합성 복합체 마우스 |
| RS63220B1 (sr) | 2011-10-28 | 2022-06-30 | Regeneron Pharma | Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc) |
| SI2818478T1 (sl) | 2011-10-28 | 2017-07-31 | Regeneron Pharmaceuticals, Inc. | Humanizirani il-6 in receptor il-6 |
| DK4389764T3 (da) | 2012-11-05 | 2026-04-13 | Regeneron Pharma | Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf |
| US9848587B2 (en) * | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| AU2014249148B2 (en) | 2013-03-11 | 2020-04-02 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
| CA2902543A1 (en) | 2013-03-11 | 2014-10-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules |
| MX2017012829A (es) | 2015-04-06 | 2018-02-23 | Regeneron Pharma | Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. |
| JP7172900B2 (ja) * | 2019-07-26 | 2022-11-16 | 株式会社デンソー | 走行中給電システム |
-
2014
- 2014-02-20 US US14/185,301 patent/US9848587B2/en active Active
- 2014-02-20 KR KR1020227006387A patent/KR102579405B1/ko active Active
- 2014-02-20 CA CA2900832A patent/CA2900832A1/en active Pending
- 2014-02-20 PT PT14708430T patent/PT2958938T/pt unknown
- 2014-02-20 RS RS20190870A patent/RS58962B1/sr unknown
- 2014-02-20 CN CN201480021698.3A patent/CN105164153B/zh active Active
- 2014-02-20 AU AU2014218897A patent/AU2014218897C1/en active Active
- 2014-02-20 SM SM20190429T patent/SMT201900429T1/it unknown
- 2014-02-20 PL PL14708430T patent/PL2958938T3/pl unknown
- 2014-02-20 JP JP2015558224A patent/JP6444895B2/ja active Active
- 2014-02-20 WO PCT/US2014/017395 patent/WO2014130671A1/en not_active Ceased
- 2014-02-20 KR KR1020217032326A patent/KR102369454B1/ko active Active
- 2014-02-20 KR KR1020157025675A patent/KR102313047B1/ko active Active
- 2014-02-20 KR KR1020237031201A patent/KR102714111B1/ko active Active
- 2014-02-20 LT LTEP14708430.5T patent/LT2958938T/lt unknown
- 2014-02-20 HU HUE14708430A patent/HUE045478T2/hu unknown
- 2014-02-20 KR KR1020247032785A patent/KR20240147707A/ko active Pending
- 2014-02-20 HR HRP20191280TT patent/HRP20191280T1/hr unknown
- 2014-02-20 SI SI201431279T patent/SI2958938T1/sl unknown
- 2014-02-20 CN CN202010208901.5A patent/CN111484999B/zh active Active
- 2014-02-20 EP EP14708430.5A patent/EP2958938B1/en active Active
- 2014-02-20 DK DK14708430.5T patent/DK2958938T3/da active
- 2014-02-20 ES ES14708430T patent/ES2736052T3/es active Active
- 2014-02-20 EP EP19159217.9A patent/EP3543253B1/en active Active
- 2014-02-20 ES ES19159217T patent/ES2987445T3/es active Active
- 2014-02-20 EP EP24155637.2A patent/EP4374690A3/en active Pending
-
2017
- 2017-10-06 US US15/727,057 patent/US10820581B2/en active Active
-
2018
- 2018-05-25 JP JP2018100545A patent/JP6752842B2/ja active Active
- 2018-11-30 AU AU2018271383A patent/AU2018271383B2/en active Active
-
2019
- 2019-07-12 CY CY20191100749T patent/CY1121979T1/el unknown
-
2020
- 2020-08-19 JP JP2020138641A patent/JP7261772B2/ja active Active
- 2020-09-24 US US17/031,255 patent/US12063915B2/en active Active
-
2021
- 2021-12-22 AU AU2021290271A patent/AU2021290271B2/en active Active
-
2022
- 2022-06-13 JP JP2022094953A patent/JP2022121465A/ja active Pending
-
2023
- 2023-11-08 JP JP2023191033A patent/JP7883476B2/ja active Active
-
2024
- 2024-07-09 US US18/766,891 patent/US20250000070A1/en active Pending
-
2025
- 2025-01-10 AU AU2025200206A patent/AU2025200206A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7763820B2 (ja) | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 | |
| JP7261772B2 (ja) | ヒト化ｔ細胞補助受容体を発現するマウス | |
| JP6866409B2 (ja) | 遺伝子改変された主要組織適合複合体マウス | |
| US11898165B2 (en) | Engineered host cells and methods of use thereof | |
| KR101964776B1 (ko) | 유전자 변형된 ｔ 세포 수용체 마우스 | |
| JP2018513683A5 (enExample) | ||
| JP2014532412A5 (enExample) | ||
| JP2016510998A5 (enExample) | ||
| AU2014249150A1 (en) | Transgenic mice expressing chimeric major histocompatibility complex (MHC) class I molecules | |
| CN118511853A (zh) | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 | |
| Shenderov et al. | Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1157-165 tumor-specific peptide | |
| KR20250077529A (ko) | 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스 | |
| Choi et al. | Ly49-dependent NK cell licensing and effector inhibition involve the same interaction site on MHC ligands | |
| HK1250884B (en) | Humanized t cell mediated immune responses in non-human animals |